You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 23, 2024

Patent: 6,270,757


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,270,757
Title: Formulations for IL-11
Abstract:The present invention provides novel formulations comprising IL-11 and glycine. Also provided are compositions, both liquid and lyophilized, comprising IL-11 and glycine and optionally, a buffering agent such as histidine and phosphate.
Inventor(s): Warne; Nicholas W. (Methuen, MA)
Assignee: Genetics Institute, Inc. (Cambridge, MA)
Application Number:08/230,982
Patent Claims:see list of patent claims

Details for Patent 6,270,757

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Wyeth Pharmaceuticals Inc. NEUMEGA oprelvekin For Injection 103694 November 25, 1997 ⤷  Sign Up 2039-03-29
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.